Dual-mode probe for detecting hydrogen sulfide and use thereof
US-2024390529-A1 · Nov 28, 2024 · US
Nanoparticle contrast agents for diagnostic imaging
US2016296641A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016296641-A1 |
| Application number | US-201615187115-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 20, 2016 |
| Priority date | Dec 29, 2008 |
| Publication date | Oct 13, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprising a nanoparticulate transition metal oxide covalently functionalized with a silane-functionalized non-targeting zwitterionic moiety.
First claim
Opening claim text (preview).
1 . A nanoparticle composition comprising nanoparticles having idealized structure IV, the nanoparticles comprising a functionalized nanoparticulate metal oxide and a trioxysilane betaine ligand wherein R 2 is independently at each occurrence a C 1 -C 3 alkyl group; R 3 is independently at each occurrence a hydrogen or a C 1 -C 3 alkyl group; n is 0, 1, 2 or 3; q is 1, 2 or 3; and the functionalized nanoparticulate metal oxide comprises nanoparticulate tantalum oxide. 2 . The nanoparticulate composition according to claim 1 , wherein each R 2 is methyl and each R 3 is hydrogen. 3 . The nanoparticulate composition according to claim 1 , wherein each R 2 is methyl and each R 3 is methyl. 4 . The nanoparticulate composition according to claim 1 , wherein n is 1, q is 1, and the functionalized nanoparticulate metal oxide consists essentially of nanoparticulate tantalum oxide. 5 . The nanoparticulate composition according to claim 4 , wherein each R 2 is methyl and each R 3 is hydrogen. 6 . A diagnostic imaging agent composition comprising nanoparticles having idealized structure IV, the nanoparticles comprising a functionalized nanoparticulate metal oxide and a trioxysilane betaine ligand wherein R 2 is independently at each occurrence a C 1 -C 3 alkyl group; R 3 is independently at each occurrence a hydrogen or a C 1 -C 3 alkyl group; n is 0, 1, 2 or 3; q is 1, 2 or 3; and the functionalized nanoparticulate metal oxide comprises nanoparticulate tantalum oxide. 7 . The diagnostic imaging agent composition according to claim 6 , further comprising a pharmaceutically acceptable carrier or excipient. 8 . The diagnostic imaging agent composition according to claim 6 , wherein the nanoparticles have a median particle size of up to 10 nm. 9 . The diagnostic imaging agent composition according to claim 6 , wherein each R 2 is methyl and each R 3 is hydrogen. 10 . The diagnostic imaging agent composition according to claim 6 , wherein each R 2 is methyl and each R 3 is hydrogen. 11 . The diagnostic imaging agent composition according to claim 10 , wherein n is 1, q is 1, and the functionalized nanoparticulate metal oxide consists essentially of tantalum oxide. 12 . The diagnostic imaging agent composition according to claim 6 , wherein the functionalized nanoparticulate metal oxide consists essentially of nanoparticulate tantalum oxide.
Assignees
Inventors
Classifications
Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title
Nanotechnology for materials or surface science, e.g. nanocomposites · CPC title
Particulate matter [e.g., sphere, flake, etc.] · CPC title
Nanoparticle, i.e. structure having three dimensions of 100 nm or less · CPC title
X-ray agent · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016296641A1 cover?
- Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprising a nanoparticulate transition metal oxide c…
- Who is the assignee on this patent?
- Gen Electric
- What technology area does this patent fall under?
- Primary CPC classification A61K49/0002. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Oct 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).